Delcath Systems Inc (DCTH) Q4 2025 Earnings Call Transcript

Why It Matters

The turnaround to profitability and aggressive site expansion position Delcath for sustained growth in the niche liver‑directed oncology market, while the CHOPIN data could broaden clinical adoption and pricing power.

Key Takeaways

• 2025 revenue $85.2M, 40% volume increase.
• 28 REMS sites; aim 40 by 2026.
• Gross margin 85% Q4, 86% FY.
• Adjusted EBITDA $25.1M, net income $2.7M.
• 2026 revenue target $100M, Hepzato ASP $175k.

Pulse Analysis

Delcath Systems’ 2025 earnings underscore a rare profitable pivot for a medical‑device firm focused on percutaneous hepatic perfusion (PHP). By delivering Hepzato to a growing cohort of uveal melanoma and liver‑metastatic patients, the company leveraged a 40% volume surge to lift revenue above $85 million, a stark contrast to the double‑digit losses recorded just a year earlier. This financial momentum is reinforced by ultra‑high gross margins—85% to 86%—that reflect the high‑value, low‑variable‑cost nature of the device, as well as a robust cash pile and a debt‑free balance sheet that give Delcath flexibility for further investment.

Pricing dynamics play a pivotal role in Delcath’s outlook. The anticipated average selling price of $175,000 per Hepzato kit incorporates a 10% discount tied to the 340B drug pricing program, which expands access for eligible hospitals while preserving margin integrity. Even with this discount, the company projects gross margins between 84% and 87% for 2026, indicating that the pricing strategy can sustain profitability despite potential variability in 340B eligibility across sites. The strong cash position and ongoing share‑repurchase program also signal confidence in the firm’s capital allocation and its ability to weather market fluctuations.

Looking ahead, the CHOPIN trial results—showing significant survival benefits when PHP is combined with checkpoint inhibitors—are poised to become a catalyst for broader clinical adoption and could reshape treatment guidelines. Coupled with an aggressive commercial rollout that expands U.S. regions from six to nine and adds new medical‑science liaisons, Delcath aims to increase active sites to 40 by the end of 2026. Parallel pipeline efforts in metastatic colorectal and breast cancer, with near‑term site activations and planned combination‑therapy studies, further diversify the revenue base and position the company for sustained growth beyond its current niche market.